Arno Therapeutics, Inc. (OTCBB: ARNI) announced today the appointment of Alexander Zukiwski, M.D., as its Chief Medical Officer, where he will be responsible for leading the clinical development and regulatory affairs teams supporting Arno’s current and future pipeline of innovative cancer therapies. “Alex has an impressive record of success in the strategic and operational execution of clinical studies and regulatory submissions of many therapeutic agents, including Taxotere ®, Xeloda ®, Procrit ®/Eprex ®, Velcade ®, Yondelis ® and Doxil ®,” said Glenn Mattes, President and Chief Executive Officer of Arno. “His expertise in global oncology drug development will be invaluable as we pursue potential new indications for our product candidates and advance our pipeline of anti-cancer agents towards registration. We are pleased to welcome him to Arno and look forward to his contributions to our future success.” “I am excited to work with my former colleague, Glenn Mattes, and the Arno Therapeutics team to successfully advance our pipeline of innovative cancer therapies,” said Dr. Zukiwski. “I believe that Arno’s compounds have the ability to become important products in the future of oncology treatment and that our team can drive the commercialization of these exciting agents.” Dr. Zukiwski was most recently Executive Vice President, Clinical Research, and Chief Medical Officer at MedImmune, Inc. where the organization he led was responsible for developing and implementing MedImmune's clinical research, medical affairs and safety strategies. Prior to joining MedImmune, Dr. Zukiwski held medical affairs and clinical development positions of increasing responsibility at Johnson & Johnson Pharmaceutical Research & Development, LLC (JJPRD), Centocor and Ortho Biotech, including serving as therapeutic area head for oncology and acting head of oncology research and development. As Vice President, Head of Clinical Oncology, he was responsible for strategic oversight and portfolio management of therapeutic oncology, hematology and supportive care clinical development programs for JJPRD and Centocor's oncology development group. Before joining Johnson & Johnson, Dr. Zukiwski held clinical oncology positions at Hoffmann-LaRoche, Glaxo Wellcome and Rhone- Poulenc Rorer.